Trial reportPsychopharmacology1996
5-HT2a/2c receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects.
Trial report in Psychopharmacology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 66 citations in OpenAlex.
- Aggression, suicidality, and intermittent explosive disorder: serotonergic correlates in personality disorder and healthy control subjects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2010Trial
- 5-HT3 receptor antagonism by ondansetron does not attenuate prolactin response to d-fenfluramine challenge in healthy human subjects.Psychopharmacology · 1996Trial
- The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.CNS drugs · 2014Review
- Associations among central nervous system serotonergic function and neuroticism are moderated by gender.Biological psychology · 2008Article
- 5HT-2C receptor polymorphism in suicide victims. Association studies in German and Slavic populations.European archives of psychiatry and clinical neuroscience · 2004Article
- Corticosteroid-serotonin interactions in depression: a review of the human evidence.Psychopharmacology · 2004Review
- Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder.Molecular psychiatry · 2001Article
- Serotonergic and noradrenergic function in depression: clinical correlates.Dialogues in clinical neuroscience · 2000Article
- Ovarian steroids and serotonin neural function.Molecular neurobiology · 1998Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Prolactin responses to d-fenfluramine (d-FEN) challenge (0.5 mg/kg PO) were examined after pre-treatment with and without the 5-HT2a/2c receptor antagonist amesergide in eight physically healthy male volunteers. Compared to pretreatment with placebo, pre-treatment with amesergide completely blocked the prolactin (PRL) response to d-FEN challenge in all subjects. These data are consistent with data demonstrating a complete blockade of the PRL response to d-FEN with the 5-HT2a/2c receptor antagonist ritanserin, and suggest that the PRL response to d-FEN challenge in humans may largely be due to activation of the 5-HT2a/2c receptor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.